Investor Relations


AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Copyright Nasdaq. Minimum 15 minutes delayed.

News Releases

AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference

SAN DIEGO , May 30, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress

Blood eosinophil level reduction consistent with clinical efficacy in ANB020 Phase 2a atopic dermatitis trial ANB020-mediated eosinophil reduction is aligned with genotypic data from prior human IL-33 loss-of-function studies Favorable safety, pharmacokinetics and pharmacodynamics observed in

AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates

Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitis and Peanut Allergy Top-Line Phase 2a Data from ANB020 in Eosinophilic Asthma Expected in the Third Quarter of 2018 SAN DIEGO , May 08, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.